Skip to content

Functional Impairment in Albinism

Functional Impairment in Albinism

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06345976
Acronym
PLAIB
Enrollment
50
Registered
2024-04-03
Start date
2024-10-01
Completion date
2025-10-01
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Albinism, Ocular

Brief summary

Albinism is a genetic and hereditary anomaly that affects pigmentation. This pathology is characterized by a deficit in melanin production. In humans, the clinical diagnosis of albinism is based on a number of factors, including : * In the integumentary region: fair skin tone, with white hair, eyelashes and eyebrows. * Ophthalmological: reduced visual acuity, photophobia, nystagmus, transilluminated blue irises, hypopigmentation of the retina at the back of the eye with fovea plana. As treatment options begin to emerge for certain albinism-induced anomalies (including, for example, the depigmentation that causes photophobia), it is desirable to understand what these patients' complaints are, and to gather their views on the emergence of treatments targeting just one of their complaints, namely glare.

Interventions

OTHERquestionnaire

On-line self-questionnaire, in the form of an 18-question form, the link to which is sent by e-mail to patients with albinism who have agreed to take part in the study.

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients with albinism * Patients \> 18 years of age * Non-opposition to study participation

Exclusion criteria

No diagnosis according to Kruijt et al. criteria Impossibility (visual, technological) of completing questionnaire

Design outcomes

Primary

MeasureTime frameDescription
To determine whether patients with albinism would be interested in a treatment that could improve their glare without improving their visual acuity.Day0To determine whether patients with albinism would be interested in a treatment that could improve their glare without improving their visual acuity. Percentage of positive responses to question Would you be interested in the possibility of a treatment for glare if it did not improve the quality of vision or visual stability?

Countries

France

Contacts

Primary ContactAmélie Yavchitz
ayavchitz@for.paris+33148036454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026